Literature DB >> 2870676

Prospects for a new acellular pertussis vaccine.

C R Manclark, D L Burns.   

Abstract

A number of virulence factors of Bordetella pertussis have been isolated and studied for their roles in pathogenesis and are under consideration, singly and in combinations, for inclusion in candidate acellular pertussis vaccines to be used in clinical trials to demonstrate safety and efficacy. Prospective immunogens would include lymphocytosis-promoting factor, agglutinogens, adenylate cyclase, filamentous haemagglutinin, heat-labile toxin and tracheal cytotoxin. Some of these factors are toxins and would need to be properly toxoided before being formulated into a vaccine. Clinical trials with acellular pertussis vaccines are planned or in progress in several countries.

Mesh:

Substances:

Year:  1985        PMID: 2870676     DOI: 10.1016/s0769-2609(85)80077-6

Source DB:  PubMed          Journal:  Ann Inst Pasteur Microbiol (1985)


  3 in total

1.  Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.

Authors:  C Weber; C Boursaux-Eude; G Coralie; V Caro; N Guiso
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.

Authors:  I P Nascimento; W O Dias; R P Mazzantini; E N Miyaji; M Gamberini; W Quintilio; V C Gebara; D F Cardoso; P L Ho; I Raw; N Winter; B Gicquel; R Rappuoli; L C Leite
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

3.  Protective effect of acellular pertussis vaccines.

Authors:  M Blennow; S Hedenskog; M Granström
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.